Forbes - Investing Information and Investing News - Forbes.com","description":"Forbes is a leading s

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-963066732&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/963066732/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Photo by Eduardo Munoz Alvarez/Getty Images)

There&s;s $350 million in student loan forgiveness available on a first-come, first served basis.

Here&s;s what you need to know and how to apply.

&l;strong&g;Temporary Expanded Public Service Loan Forgiveness

&l;/strong&g;

On Wednesday, the U.S. Department of Education &l;a href=&q;https://studentaid.ed.gov/sa/repay-loans/forgiveness-cancellation/public-service/temporary-expanded-public-service-loan-forgiveness?utm_content=&a;amp;utm_medium=email&a;amp;utm_name=&a;amp;utm_source=govdelivery&a;amp;utm_term=&q; target=&q;_blank&q;&g;added&l;/a&g; a page to its website with details of the Temporary Expanded Public Service Loan Forgiveness program.

The Consolidated Appropriations Act of 2018 appropriated $350 million in funds for student loan borrowers who previously chose an ineligible repayment plan as part of the Public Service Loan Forgiveness program.

If you meet all the requirements for the Public Service Loan Forgiveness program, but were enrolled in an ineligible repayment plan (namely the graduated or extended repayment plans), then now you may have a second chance for student loan forgiveness.

The funds are available until they are exhausted.

&l;strong&g;How To Apply For Temporary Expanded Public Service Loan Forgiveness&l;/strong&g;

The &l;a href=&q;https://www.makelemonade.co/public-service-loan-forgiveness-guide/&q; target=&q;_blank&q; rel=&q;nofollow noopener noreferrer&q; target=&q;_blank&q;&g;Public Service Loan Forgiveness&l;/a&g; program is a federal program that forgives federal student loans for borrowers who are employed full-time (more than 30 hours per week) in an eligible federal, state or local public service job or 501(c)(3) non-profit job who make 120 eligible on-time payments over 10 years.

More than 700,000 borrowers have completed an employment certification form for the Public Service Loan Forgiveness program. However, many don&s;t meet the requirements.

Here&s;s what you need to know to ensure that you qualify:

&l;strong&g;1. You must work for a qualifying public service employer in a qualifying public service role&l;/strong&g;

You must work in a qualifying public service role for a qualifying employer. Typically, there are two general types:

- state, local and federal government

- 501(c)(3) non-profit

If you work for another employer not covered under these two categories, you can contact the U.S. Department of Education to determine if your role and organization qualify.

&l;strong&g;2. You must have direct, federal student loans&l;/strong&g;

The Public Service Loan Forgiveness program does not forgive private student loans - even if you work in public service.

If you work in the private sector or work for a non-profit in a non-public service role, you will not qualify for this program. You must have Direct, federal student loans such as Stafford loans to qualify.

You can confirm with your student loan servicer that you have Direct student loans, or check through Federal Student Aid.

You also can consolidate your federal student loans into a Direct Consolidation Loan with the federal government to qualify for Public Service Loan Forgiveness.

&l;strong&g;3. You must be enrolled in a federal repayment program&l;/strong&g;

You also must be enrolled in an income-driven federal repayment program. You then must make 120 on-time, monthly payments (over 10 years) to qualify.

You can determine which student loan repayment plan works best for you with these &l;a href=&q;https://www.makelemonade.co/calculators&q; target=&q;_blank&q;&g;student loan calculators&l;/a&g;.

&l;strong&g;4. You must have applied for Public Service Loan Forgiveness and have been rejected&l;/strong&g;

You must have had your application denied only because some or all of your payments were not made under a qualifying repayment plan for Public Service Loan Forgiveness.

&l;strong&g;What are the additional qualifying repayment plans?&l;/strong&g;

The Education Department will reconsider your application with an expanded list of qualifying repayment plans, even if these repayment plans do not usually count under Public Service Loan Forgiveness.

The additional qualifying repayment plans include the Graduated Repayment Plan, Extended Repayment Plan, Consolidation Standard Repayment Plan and Consolidation Graduated Repayment Plan.

&l;strong&g;How do you apply for Temporary Expanded Public Service Loan Forgiveness?&l;/strong&g;

Follow these three steps:

Follow these steps to request TEPSLF consideration:

&l;/p&g;&l;ol&g;&l;li&g;Email FedLoan Servicing to request that the Education Department reconsider your eligibility for Public Service Loan Forgiveness.&l;/li&g;

&l;li&g;Include the same name under which you submitted your Public Service Loan Forgiveness application and your date of birth in the email.&l;/li&g;

&l;li&g;Send the email to &l;a id=&q;anch_129&q; href=&q;mailto:TEPSLF@myfedloan.org&q; target=&q;_blank&q;&g;TEPSLF@myfedloan.org&l;/a&g;.&l;/li&g;

&l;/ol&g;

Here is a sample template email that you can use:

To: TEPSLF@myfedloan.org

Subject: TEPSLF request

I request that the U.S. Department of Education respectfully reconsider my eligibility for public service loan forgiveness.

&l;ul&g;&l;li&g;Name: &l;/li&g;

&l;li&g;Date of Birth: &l;/li&g;

&l;/ul&g;

Thank you for your consideration.

Sincerely,

Your Name

You will receive a response from FedLoan Servicing once your request has been reviewed. Separately, you can contact FedLoan Servicing at 1-855-265-4038 from 8 a.m.&a;ndash; 9 p.m. Eastern time, Monday through Friday.

&l;strong&g;Can Your Loan Be Forgiven Under This Program Even If You Don&s;t Work In Public Service?&l;/strong&g;

While your student loans won&s;t be forgiven, you may be able to lower your interest rate through student loan refinancing. A lower interest rate can save substantial interest payments over the life of your student loans.

With &l;a href=&q;https://www.makelemonade.co/5-reasons-refinance-student-loans/&q; target=&q;_blank&q;&g;student loan refinance&l;/a&g;, you can combine your existing private student loans and/or federal student loans into a new, single student loan with a lower interest rate and one monthly payment. Your new student loan will be a private student loan with a single student loan servicer, which makes it easier to manage your monthly payment.

You won&s;t have access to federal repayment plans and benefits, but many private student loan lenders now offer forbearance and deferral programs for economic hardship.

With student loan refinancing, depending on your current interest rate, loan balance, income and credit profile, you could receive a lower interest rate that could help you save substantially. The higher your loan balance, the more you can potentially save.

&l;!--donotpaginate--&g;

Reliance Trust Co. of Delaware Sells 2,073 Shares of Chevron Co. (CVX)

Reliance Trust Co. of Delaware trimmed its holdings in Chevron Co. (NYSE:CVX) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 49,967 shares of the oil and gas company’s stock after selling 2,073 shares during the period. Chevron makes up approximately 0.9% of Reliance Trust Co. of Delaware’s holdings, making the stock its 15th largest holding. Reliance Trust Co. of Delaware’s holdings in Chevron were worth $6,255,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Fusion Family Wealth LLC grew its position in Chevron by 192.6% in the 4th quarter. Fusion Family Wealth LLC now owns 1,273 shares of the oil and gas company’s stock valued at $159,000 after buying an additional 838 shares during the last quarter. Lenox Wealth Advisors Inc. grew its position in Chevron by 15,555.6% in the 4th quarter. Lenox Wealth Advisors Inc. now owns 1,409 shares of the oil and gas company’s stock valued at $176,000 after buying an additional 1,400 shares during the last quarter. Lesa Sroufe & Co purchased a new position in Chevron in the 3rd quarter valued at $201,000. WCM Investment Management CA purchased a new position in Chevron in the 4th quarter valued at $202,000. Finally, Independence Trust CO purchased a new position in Chevron in the 4th quarter valued at $204,000. 64.42% of the stock is currently owned by institutional investors and hedge funds.

Get Chevron alerts:

In related news, CEO Michael K. Wirth sold 130,000 shares of the business’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $128.00, for a total value of $16,640,000.00. Following the completion of the transaction, the chief executive officer now owns 130,000 shares of the company’s stock, valued at approximately $16,640,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP R. Hewitt Pate sold 25,500 shares of the business’s stock in a transaction dated Tuesday, April 17th. The shares were sold at an average price of $121.97, for a total transaction of $3,110,235.00. Following the completion of the transaction, the vice president now directly owns 25,500 shares of the company’s stock, valued at approximately $3,110,235. The disclosure for this sale can be found here. Insiders sold a total of 386,500 shares of company stock valued at $49,748,880 in the last three months. 0.46% of the stock is currently owned by corporate insiders.

Shares of Chevron opened at $122.19 on Monday, Marketbeat reports. Chevron Co. has a twelve month low of $102.55 and a twelve month high of $133.88. The stock has a market capitalization of $233.41 billion, a P/E ratio of 33.02, a PEG ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.04 and a quick ratio of 0.84.

Chevron (NYSE:CVX) last announced its earnings results on Friday, April 27th. The oil and gas company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.45. Chevron had a net margin of 6.95% and a return on equity of 5.83%. The firm had revenue of $37.76 billion during the quarter, compared to the consensus estimate of $40.34 billion. During the same quarter in the previous year, the company posted $1.23 EPS. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. analysts expect that Chevron Co. will post 7.6 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, June 11th. Investors of record on Friday, May 18th will be paid a $1.12 dividend. This represents a $4.48 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Thursday, May 17th. Chevron’s payout ratio is 121.08%.

A number of research firms recently weighed in on CVX. Royal Bank of Canada upgraded shares of Chevron from an “underperform” rating to a “sector perform” rating and set a $125.00 price objective on the stock in a research report on Friday, February 9th. Credit Suisse Group boosted their target price on shares of Chevron from $129.00 to $132.00 and gave the stock a “neutral” rating in a research report on Monday, April 30th. Vetr lowered shares of Chevron from a “strong-buy” rating to a “buy” rating and set a $122.05 target price on the stock. in a research report on Monday, February 26th. DZ Bank upgraded shares of Chevron from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Finally, Societe Generale upgraded shares of Chevron from a “hold” rating to a “buy” rating in a research report on Friday, February 2nd. Seven research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $133.52.

Chevron Company Profile

Chevron Corporation, through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as operates a gas-to-liquids plant.

Want to see what other hedge funds are holding CVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chevron Co. (NYSE:CVX).

Billionaire owner of Le Figaro and Dassault Aviation dies

The billionaire owner of France's Le Figaro newspaper and jet maker Dassault has died.

Serge Dassault was 93 when he passed away on Monday, his family announced.

The industrialist and media magnate was one of France's richest men, with a fortune estimated by Forbes at about $26 billion.

In a short statement, the Dassault family announced that Serge Dassault "died at his office on the Champs �lys茅es, following a heart attack."

In an article published on its website, Le Figaro described him as "the head of one of the wealthiest dynasties in France and one of the most influential and powerful family holdings."

The diversified group he inherited from his father �� Marcel Dassault �� employs about 18,000 people and is a world leader in aviation, making Falcon private jets as well as the Mirage 2000 and Rafale fighter aircraft.

It owns Dassault Syst猫mes (DASTY), which provides 3D computer-aided design software for industry, wine estates, an auction house and several very valuable works of art.

Serge Dassault also had a political career, serving as a conservative senator and mayor.

-- Saskya Vandoorne contributed to this article

Qts Realty Trust Inc (QTS) CEO Chad L. Williams Bought $1.8 million of Shares

CEO of Qts Realty Trust Inc (NYSE:QTS) Chad L. Williams bought 50,000 shares of QTS on 05/23/2018 at an average price of $35.68 a share. The total cost of this purchase was $1.8 million.

QTS Realty Trust Inc is a real estate investment trust in the United States. Its properties mainly include data centers which are mainly located in the United States and in other locations such as Canada, Europe, and Asia. QTS Realty Trust Inc has a market cap of $1.93 billion; its shares were traded at around $37.80 with and P/S ratio of 4.56. The dividend yield of QTS Realty Trust Inc stocks is 4.19%. QTS Realty Trust Inc had annual average EBITDA growth of 13.70% over the past five years.

CEO Recent Trades:

CEO Chad L. Williams bought 50,000 shares of QTS stock on 05/23/2018 at the average price of $35.68. The price of the stock has increased by 5.94% since.CEO Chad L. Williams bought 62,757 shares of QTS stock on 05/22/2018 at the average price of $34.86. The price of the stock has increased by 8.43% since.

CFO Recent Trades:

CFO Jeffrey H. Berson bought 15,000 shares of QTS stock on 05/21/2018 at the average price of $34.89. The price of the stock has increased by 8.34% since.

Directors and Officers Recent Trades:

Chief People Officer Steven C Bloom bought 1,000 shares of QTS stock on 05/23/2018 at the average price of $35.08. The price of the stock has increased by 7.75% since.Director Philip P Trahanas bought 60,000 shares of QTS stock on 05/21/2018 at the average price of $34.72. The price of the stock has increased by 8.87% since.Director Peter Marino bought 10,000 shares of QTS stock on 05/21/2018 at the average price of $34.51. The price of the stock has increased by 9.53% since.

For the complete insider trading history of QTS, click here

.

First Midwest Bancorp (FMBI) Reaches New 1-Year High and Low at $26.92

First Midwest Bancorp (NASDAQ:FMBI) reached a new 52-week high and low during mid-day trading on Tuesday . The company traded as low as $26.92 and last traded at $26.74, with a volume of 58961 shares trading hands. The stock had previously closed at $26.22.

A number of equities research analysts have recently issued reports on the stock. UBS upgraded shares of First Midwest Bancorp from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 28th. Raymond James upgraded shares of First Midwest Bancorp from a “market perform” rating to an “outperform” rating in a report on Wednesday, March 28th. Zacks Investment Research lowered shares of First Midwest Bancorp from a “buy” rating to a “hold” rating in a report on Tuesday, February 13th. BidaskClub lowered shares of First Midwest Bancorp from a “buy” rating to a “hold” rating in a report on Saturday, April 28th. Finally, ValuEngine lowered shares of First Midwest Bancorp from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $26.67.

Get First Midwest Bancorp alerts:

The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 0.61. The firm has a market cap of $2.72 billion, a PE ratio of 19.44, a P/E/G ratio of 2.33 and a beta of 1.13.

First Midwest Bancorp (NASDAQ:FMBI) last issued its earnings results on Tuesday, April 24th. The financial services provider reported $0.33 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.38 by ($0.05). First Midwest Bancorp had a net margin of 16.08% and a return on equity of 7.59%. The company had revenue of $154.08 million during the quarter, compared to analysts’ expectations of $160.44 million. During the same period last year, the business posted $0.34 earnings per share. equities research analysts forecast that First Midwest Bancorp will post 1.62 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 10th. Shareholders of record on Friday, June 29th will be issued a $0.11 dividend. The ex-dividend date is Thursday, June 28th. This represents a $0.44 dividend on an annualized basis and a yield of 1.68%. First Midwest Bancorp’s dividend payout ratio (DPR) is presently 32.59%.

In other First Midwest Bancorp news, EVP Michael C. Spitler sold 10,000 shares of the stock in a transaction dated Wednesday, May 2nd. The shares were sold at an average price of $24.68, for a total value of $246,800.00. Following the completion of the transaction, the executive vice president now directly owns 26,174 shares of the company’s stock, valued at $645,974.32. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert P. Omeara sold 5,200 shares of the stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $26.50, for a total transaction of $137,800.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,382 shares of company stock valued at $2,635,462. 1.69% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. increased its holdings in First Midwest Bancorp by 2.7% in the first quarter. Principal Financial Group Inc. now owns 800,384 shares of the financial services provider’s stock valued at $19,682,000 after buying an additional 20,910 shares in the last quarter. Summit Trail Advisors LLC increased its holdings in First Midwest Bancorp by 2,114.0% in the first quarter. Summit Trail Advisors LLC now owns 150,664 shares of the financial services provider’s stock valued at $151,000 after buying an additional 143,859 shares in the last quarter. Xact Kapitalforvaltning AB increased its holdings in First Midwest Bancorp by 44.9% in the first quarter. Xact Kapitalforvaltning AB now owns 17,432 shares of the financial services provider’s stock valued at $429,000 after buying an additional 5,400 shares in the last quarter. Atlantic Trust Group LLC increased its holdings in First Midwest Bancorp by 47.9% in the first quarter. Atlantic Trust Group LLC now owns 31,028 shares of the financial services provider’s stock valued at $763,000 after buying an additional 10,054 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in First Midwest Bancorp by 2.2% in the first quarter. Legal & General Group Plc now owns 211,510 shares of the financial services provider’s stock valued at $5,192,000 after buying an additional 4,615 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

About First Midwest Bancorp

First Midwest Bancorp, Inc operates as a bank holding company for First Midwest Bank that provides various banking products and services. The company accepts checking, NOW, money market, and savings accounts, as well as various types of short-term and long-term certificates of deposit. Its loan products include working capital loans and lines of credit; accounts receivable financing; inventory and equipment financing; sector-based lending, including healthcare, asset-based lending, structured finance, and syndications; agricultural loans; and mortgages, home equity lines and loans, personal loans, specialty loans, and auto loans, as well as funding for the construction, purchase, refinance, or improvement of commercial real estate properties.

Synthetic Biologics, Inc. (SYN) Receives Consensus Rating of “Hold” from Brokerages

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) has earned a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $2.63.

Several analysts have commented on SYN shares. HC Wainwright started coverage on shares of Synthetic Biologics in a research report on Friday. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of Synthetic Biologics from a “sell” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Saturday, May 12th. Finally, Griffin Securities cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th.

Get Synthetic Biologics alerts:

Shares of Synthetic Biologics opened at $0.25 on Friday, Marketbeat.com reports. Synthetic Biologics has a 52 week low of $0.23 and a 52 week high of $0.27.

Synthetic Biologics (NYSEAMERICAN:SYN) last issued its earnings results on Tuesday, May 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03.

Several institutional investors and hedge funds have recently added to or reduced their stakes in SYN. Citadel Advisors LLC boosted its stake in Synthetic Biologics by 312.1% in the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock worth $122,000 after purchasing an additional 183,120 shares during the period. Virtu Financial LLC boosted its stake in Synthetic Biologics by 256.1% in the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock worth $152,000 after purchasing an additional 215,440 shares during the period. Blair William & Co. IL boosted its stake in Synthetic Biologics by 14.8% in the 1st quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock worth $631,000 after purchasing an additional 255,096 shares during the period. Finally, 683 Capital Management LLC acquired a new position in Synthetic Biologics in the 4th quarter worth $762,000.

About Synthetic Biologics

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Zacks: Brokerages Expect Agios Pharmaceuticals (AGIO) to Post -$1.66 EPS

Equities research analysts forecast that Agios Pharmaceuticals (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.66) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Agios Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.69) and the highest estimate coming in at ($1.62). Agios Pharmaceuticals posted earnings of ($1.78) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6.7%. The firm is expected to issue its next earnings results on Tuesday, August 14th.

On average, analysts expect that Agios Pharmaceuticals will report full-year earnings of ($6.51) per share for the current year, with EPS estimates ranging from ($6.73) to ($6.40). For the next financial year, analysts anticipate that the company will post earnings of ($4.83) per share, with EPS estimates ranging from ($6.30) to ($0.89). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Agios Pharmaceuticals.

Get Agios Pharmaceuticals alerts:

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The business’s revenue for the quarter was down 16.2% compared to the same quarter last year. During the same period last year, the company posted ($1.56) EPS.

A number of analysts have recently weighed in on the company. Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. SunTrust Banks set a $115.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 7th. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, April 17th. Finally, BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $88.40.

NASDAQ:AGIO opened at $86.99 on Wednesday. The company has a market cap of $4.95 billion, a PE ratio of -12.89 and a beta of 1.98. Agios Pharmaceuticals has a fifty-two week low of $45.96 and a fifty-two week high of $89.33.

In related news, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Monday, April 23rd. The stock was sold at an average price of $85.95, for a total value of $176,197.50. Following the completion of the sale, the insider now owns 2,050 shares of the company’s stock, valued at $176,197.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher Bowden sold 2,000 shares of the firm’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares of the company’s stock, valued at approximately $245,173.10. The disclosure for this sale can be found here. Insiders sold 62,950 shares of company stock valued at $5,102,838 in the last ninety days. 3.02% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Profund Advisors LLC raised its holdings in Agios Pharmaceuticals by 4.3% in the first quarter. Profund Advisors LLC now owns 15,875 shares of the biopharmaceutical company’s stock worth $1,298,000 after purchasing an additional 649 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares in the last quarter. California Public Employees Retirement System raised its holdings in Agios Pharmaceuticals by 3.4% in the third quarter. California Public Employees Retirement System now owns 36,100 shares of the biopharmaceutical company’s stock worth $2,410,000 after purchasing an additional 1,200 shares in the last quarter. State of Wisconsin Investment Board raised its holdings in Agios Pharmaceuticals by 15.7% in the first quarter. State of Wisconsin Investment Board now owns 9,904 shares of the biopharmaceutical company’s stock worth $810,000 after purchasing an additional 1,345 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares in the last quarter. Institutional investors and hedge funds own 82.13% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com